Navigation Links
Brazil proves developing countries can use generic medicines to fight HIV/AIDS epidemic
Date:7/13/2009

PROVIDENCE, R.I. [Brown University] Brazil's nearly two-decade effort to treat people living with HIV and AIDS shows that developing countries can successfully combat the epidemic. Inexpensive generic medicines are a large part of the solution, say researchers from Brown University and the Harvard School of Public Health.

Brazil did this, researchers said, largely by pursuing controversial policies that prompted pharmaceutical companies with exclusive drugs to lower their prices dramatically and generic companies to develop lower-cost alternatives for use in emerging markets.

"Brazil has proved it is possible to treat people with AIDS in developing countries," said lead author Amy Nunn, assistant professor of medicine (research) at The Warren Alpert Medical School of Brown University. She added that the country saved more than $1 billion as a result of bargaining with multinational pharmaceutical companies, resulting in significant changes in global AIDS policy.

That effort, Nunn said, has had a wide impact.

"Before Brazil's efforts, as recently as the year 2000," she said, "most people living with HIV/AIDS in developing countries died without receiving treatment."

Details of their findings will be published in the July/August issue of Health Affairs. Francisco Bastos, a well-known AIDS epidemiologist at the Oswaldo Cruz Foundation in Rio de Janiero, and Elize da Fonseca at the University of Edinburgh in Scotland also participated in the research. Senior author Sofia Gruskin is an associate professor of health and human rights at the Harvard School of Public Health in Boston, where the initial research began.

One of the biggest advances in Brazil's push to address the advance of HIV and AIDS came in the 1990s, when the country passed a law guaranteeing free, universal access to drugs for AIDS treatment. The country also began producing generic AIDS medicines in public factories. Brazilian authori
'/>"/>

Contact: Mark Hollmer
Mark_Hollmer@brown.edu
401-863-1862
Brown University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma
2. New Swine Flu Strain Found in Brazil: Report
3. PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil
4. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
5. Top Book on Cosmetic Surgery Anesthesia to be Released in Portuguese in Brazil, World Leader in Cosmetic Surgery
6. Growth Opportunity in Brazils Varicose Vein Treatment Device Market
7. Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun
8. Pitt receives $2.8 million to train HIV/AIDS researchers in Mozambique, Brazil and India
9. Innovation and Strategic Alliances Come to the Rescue of Participants in Mature Brazilian Market for Food Emulsifiers, Finds Frost & Sullivan
10. Companion Global Healthcare Clients May Choose Brazil for JCI-Accredited Care
11. Statement From Sequella Founder and CEO, Dr. Carol Nacy at the Stop TB Meeting in Brazil on the Eve of World TB Day
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 1ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 2ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 3ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non Surgical Treatment of Eye Disease 5051 4Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 1Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 2Mount Sinai leads unprecedented NIH supported attempt to discover rules for assembling human tissue 58221 3Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 1Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 10079 3